Eli Lilly's monoclonal antibody, Kisunla (donanemab), has seen a turnaround at the European Medicines Agency’s CHMP. Following an earlier rejection due to safety concerns and unclear benefits in slowing Alzheimer’s progression, the CHMP now recommends approval for patients who are ApoE4 heterozygotes or non-carriers. This shift contrasts with the EMA’s previous stance and offers a path forward for this early-stage Alzheimer’s therapy amid ongoing debates about benefit-risk balance in neurodegenerative disease treatments.